ArticleJournal of pediatric endocrinology & metabolism : JPEM2011
Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.
Article in Journal of pediatric endocrinology & metabolism : JPEM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.Clinical trials (London, England) · 2024Review
- Endocrine and non-endocrine causes of fatigue in adults with Neurofibromatosis type 1.Frontiers in endocrinology · 2023Review
- Bone densitometry measurements in children with neurofibromatosis Type 1 using quantitative computed tomography.Singapore medical journal · 2022Article
- Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.Scientific reports · 2022Article
- The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.Journal of musculoskeletal & neuronal interactions · 2022Review
- Endocrine system involvement in patients with RASopathies: A case series.Frontiers in endocrinology · 2022Article
- Review
- Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.Current treatment options in oncology · 2020Review
- Vitamin D Status and VDR Genotype in NF1 Patients: A Case-Control Study from Southern Brazil.International journal of endocrinology · 2015Article
- Diagnosis and treatment of osteopenic fractures in children.Current osteoporosis reports · 2012Review
- Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveLow 25-hydroxyvitamin D (25OHD) concentrations have been associated with tumors and osteopenia or fractures in adults with neurofibromatosis type 1 (NF1). We report 25OHD concentrations in 109 children with NF1 and 218 controls matched for age, sex, geographic location, and time of year.
methodsChildren with NF1 were recruited (n=109; 2-17 years), and clinical data and dual-energy X-ray absorptiometry measurements were obtained. 25OHD concentrations were measured in subjects and controls.
resultsMore NF1 individuals (50%) were in the 25OHD insufficient or deficient range (<30 ng/mL) (1 ng/mL = 2.496 nmol/L) compared to controls (36%) (p = 0.0129). 25OHD concentrations were higher in individuals with neurofibromas after controlling for age (p = 0.0393), and were negatively associated with whole-body subtotal bone mineral density (BMD) z-scores (p = 0.0385).
conclusionsMore children with NF1 had 25OHD concentrations <30 ng/mL, potentially because of increased pigmentation and/or decreased sunlight exposure. In contrast to adults, decreased 25OHD concentrations were not associated with neurofibromas, and there was no positive association between 25OHD and BMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.